Pliant Therapeutics, Inc.
(NASDAQ : PLRX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
REGNRegeneron Pharmaceuticals, Inc. 1.32%697.332.6%$644.85m
MRNAModerna, Inc. -0.55%123.640.0%$634.51m
AMGNAmgen, Inc. -0.34%226.971.4%$624.69m
GILDGilead Sciences, Inc. -1.43%62.861.0%$494.49m
VRTXVertex Pharmaceuticals, Inc. -1.01%283.451.9%$355.83m
ILMNIllumina, Inc. -1.61%190.383.2%$291.37m
SNSSSunesis Pharmaceuticals, Inc. -5.81%4.050.7%$283.11m
BIIBBiogen, Inc. -1.42%197.781.8%$184.42m
SAVACassava Sciences, Inc. -18.00%41.870.0%$173.71m
BNTXBioNTech SE -1.27%128.350.0%$100.39m
NRBONeuroBo Pharmaceuticals, Inc. -6.44%15.540.0%$89.03m
NVAXNovavax, Inc. -6.42%21.0075.6%$85.66m
BMRNBioMarin Pharmaceutical, Inc. -0.09%84.844.2%$76.07m
EXASEXACT Sciences Corp. -2.74%33.4117.6%$71.49m
CRSPCRISPR Therapeutics AG -2.68%63.160.6%$69.53m

Company Profile

Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.